• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

    9.145 -1.745 (-16.02%)
    Streaming Delayed Price Updated: 2:06 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,562,076
    Open 9.650
    Bid (Size) 9.120 (200)
    Ask (Size) 9.170 (600)
    Prev. Close 10.89
    Today's Range 8.760 - 10.42
    52wk Range 2.315 - 15.74
    Shares Outstanding 61,758,994
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗
    Via Chartmill
    News headline image
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -16.3%
    -16.3%
    1 Month
    -16.2%
    -16.2%
    3 Month
    -22.1%
    -22.1%
    6 Month
    +42.7%
    +42.7%
    1 Year
    +147.2%
    +147.2%

    More News

    Read More
    News headline image
    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For October 29, 2025 ↗
    Via Benzinga
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
    Via AB Newswire
    News headline image
    Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes ↗
    Via Stocktwits
    News headline image
    Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
    Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
    The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
    What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
    The current price of Fulcrum Therapeutics, Inc. - Common Stock is 9.145
    When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
    The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 02/24/26 02:06 PM ET
    What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
    The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 564.79M
    How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
    Fulcrum Therapeutics, Inc. - Common Stock has 565M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.